Oon C J, Rauff A, Tan L K
University Department of Medicine, Singapore General Hospital.
Cancer Chemother Pharmacol. 1989;23 Suppl:S13-6. doi: 10.1007/BF00647231.
Between January 1977 and July 1987, 3200 patients with hepatocellular carcinoma (HCC) were studied in Singapore. HCC formed 90% of primary liver cancers seen in Singapore and is the second most common fatal malignancy seen in men in the country. Extensive clinical and basic research has defined certain treatment strategies. Of importance is the prompt detection of early nodular tumours, which can be resected. Resection, 'targetting' with anticancer drugs and, in selected cases, synchronised direct hepatic irradiation with adriamycin, used as a radiosensitiser, have been promising treatment methods. Biological modifiers, such as interferons and interleukins, offer potential for the future. Preliminary pilot studies suggest that interferons may prevent the development of HCC, but more studies are required. Similarly, selective localisation of anticancer agents with radio-isotopical agents opens opportunities for treatment.
1977年1月至1987年7月期间，新加坡对3200例肝细胞癌（HCC）患者进行了研究。HCC占新加坡原发性肝癌的90%，是该国男性中第二常见的致命恶性肿瘤。广泛的临床和基础研究已经确定了某些治疗策略。重要的是要迅速检测出可切除的早期结节性肿瘤。手术切除、用抗癌药物“靶向治疗”，以及在某些情况下，同步使用阿霉素作为放射增敏剂进行直接肝脏照射，都是很有前景的治疗方法。生物调节剂，如干扰素和白细胞介素，为未来提供了潜力。初步的试点研究表明，干扰素可能会预防HCC的发生，但还需要更多的研究。同样，用放射性同位素试剂对抗癌药物进行选择性定位为治疗提供了机会。
